ACADIA Pharmaceuticals (NASDAQ:ACAD) encountered a drop of 0.7% or -139,543 shares in the short positions. The number dropped from 20,625,398 on May 31,2016 to 20,485,855 on June 15,2016. The final interest is 18.2% of the floated stock. The days to cover figure of 7 can be arrived using the average daily exchange of 2,829,193 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock opened at $30.88 on Friday but the bulls could not build on the opening and the stock topped out at $32.90 for the day. The stock traded down to $30.09 during the day, due to lack of any buying support eventually closed down at $31.43 with a loss of -6.18% for the day. The stock had closed at $33.50 on the previous day. The total traded volume was 9,672,341 shares.
The company shares have dropped -21.15% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $51.99 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $34.73 and the 200 Day Moving Average price is recorded at $28.53.
ACADIA Pharmaceuticals (NASDAQ:ACAD) has tumbled 15.99% during the past week and has dropped 11.74% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 14.59%. ACADIA Pharmaceuticals (NASDAQ:ACAD) has underperformed the index by 9.07% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.